» Articles » PMID: 10573511

Independent Predictors of Liver Fibrosis in Patients with Nonalcoholic Steatohepatitis

Overview
Journal Hepatology
Specialty Gastroenterology
Date 1999 Nov 26
PMID 10573511
Citations 461
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic steatohepatitis (NASH) may present with increased hepatic fibrosis progressing to end-stage liver disease. No factors that determine increasing fibrosis and histologically advanced disease have been recognized, thus, liver biopsy is recommended in all patients for diagnosis and prognosis. Our aim was to identify independent predictors of severe hepatic fibrosis in patients with NASH. One hundred and forty-four patients were studied. All patients underwent liver biopsy. Clinical and biochemical variables were examined with univariate and multivariate analysis. Thirty-seven (26%) patients had no abnormal fibrosis, 53 (37%) had mild fibrosis, 15 (10%) had moderate fibrosis, 14 (10%) had bridging fibrosis, and 25 (17%) had cirrhosis. In multivariate analysis, older age (P =. 001), obesity (P =.002), diabetes mellitus (P =.009), and aspartate transaminase/alanine transaminase (AST/ALT) ratio greater than 1 (P =.03) were significant predictors of severe liver fibrosis (bridging/cirrhosis). Body mass index (P =.003) was the only independent predictor of the degree of fat infiltration. Increased transferrin saturation correlated positively with the severity of fibrosis (P =.02) in univariate analysis, and there was a trend for more female patients among those with more advanced fibrosis (P =. 09). However, iron studies or gender were not significant when controlled for age, obesity, diabetes, and AST/ALT ratio. In conclusion, older age, obesity, and presence of diabetes mellitus help identify those NASH patients who might have severe liver fibrosis. This is the subgroup of patients with NASH who would be expected to derive the most benefit from having a liver biopsy and considering investigational therapies.

Citing Articles

Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.

Hanamatsu H, Suda G, Ohara M, Ogawa K, Tamaki N, Hikita H J Gastroenterol. 2025; .

PMID: 39849179 DOI: 10.1007/s00535-024-02206-8.


Hepatic and Pancreatic Cellular Response to Early Life Nutritional Mismatch.

Ghosh S, Ganguly A, Habib M, Shin B, Thamotharan S, Andersson S Endocrinology. 2025; 166(3).

PMID: 39823439 PMC: 11815087. DOI: 10.1210/endocr/bqaf007.


Impact of diabetes on long-term survival in elderly liver cancer patients: A retrospective study.

Chen D, Gao X, Wang Y Open Med (Wars). 2025; 20(1):20241096.

PMID: 39822990 PMC: 11737364. DOI: 10.1515/med-2024-1096.


Active role of the immune system in metabolic dysfunction-associated steatotic liver disease.

Mori T, Yoshio S, Kakazu E, Kanto T Gastroenterol Rep (Oxf). 2024; 12:goae089.

PMID: 39411101 PMC: 11479709. DOI: 10.1093/gastro/goae089.


Exploring the Relationship of rs2802292 with Diabetes and NAFLD in a Southern Italian Cohort-Nutrihep Study.

Forte G, Donghia R, Lepore Signorile M, Tatoli R, Bonfiglio C, Losito F Int J Mol Sci. 2024; 25(17).

PMID: 39273459 PMC: 11394752. DOI: 10.3390/ijms25179512.